OmniAb (NASDAQ:OABIW) versus Harvard Bioscience (NASDAQ:HBIO) Head-To-Head Comparison

OmniAb (NASDAQ:OABIW) and Harvard Bioscience (NASDAQ:HBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares OmniAb and Harvard Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46 million	N/A	N/A	N/A	N/A
Harvard Bioscience	$86.55 million	0.32	-$56.70 million	($2.17)	-2.87

OmniAb has higher earnings, but lower revenue than Harvard Bioscience.

Insider & Institutional Ownership

80.9% of Harvard Bioscience shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares OmniAb and Harvard Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Analyst Ratings

This is a breakdown of current recommendations and price targets for OmniAb and Harvard Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0	0	0	0	0.00
Harvard Bioscience	1	1	1	0	2.00

Harvard Bioscience has a consensus target price of $6.75, indicating a potential upside of 8.52%. Given Harvard Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than OmniAb.

Summary

Harvard Bioscience beats OmniAb on 6 of the 9 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.